<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896934</url>
  </required_header>
  <id_info>
    <org_study_id>130360</org_study_id>
    <secondary_id>R21MH099218-01A1</secondary_id>
    <nct_id>NCT01896934</nct_id>
  </id_info>
  <brief_title>Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression</brief_title>
  <official_title>Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression (R21)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-term goal of this line of research is to determine if decreased vascular reactivity&#xD;
      and frontal hypoperfusion is associated with poor response antidepressants. Such perfusion&#xD;
      deficits could contribute to antidepressant nonresponse as they would hinder improvements in&#xD;
      dorsal system metabolism seen with antidepressant treatment. The objective of the current&#xD;
      proposal is to determine if decreased vascular reactivity and frontal hypoperfusion in&#xD;
      depressed elders predicts and persists with antidepressant nonremission. The investigators&#xD;
      will pursue the primary aim testing the hypothesis that decreased reactivity and&#xD;
      hypoperfusion, specifically in the dorsolateral prefrontal cortex and dorsal anterior&#xD;
      cingulate cortex, predict antidepressant nonremission. The investigators will enroll 40&#xD;
      depressed elders who will complete clinical, cognitive, and MRI assessments before and after&#xD;
      a 12-week open-label antidepressant trial of sertraline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term goal of this line of research is to determine if in late-life depression (LLD),&#xD;
      cerebrovascular dysregulation is predictive of antidepressant outcomes. The investigators&#xD;
      hypothesize that vascular pathology resulting in reduced cerebrovascular reactivity&#xD;
      contributes to frontocingulate hypoperfusion. Such pathology would impair neurovascular&#xD;
      coupling and reduce the ability of the vasculature to improve frontocingulate perfusion&#xD;
      during antidepressant treatment. Thus decreased cerebrovascular reactivity and perfusion may&#xD;
      be a biomarker of antidepressant nonresponse. As an initial step in this research, the&#xD;
      current study will utilize MRI arterial spin labeling (ASL) to examine if cerebrovascular&#xD;
      reactivity deficits and resting cerebral blood flow (CBF) deficits predict antidepressant&#xD;
      nonremission in LLD. The rationale for this proposal is that it will identify mechanisms by&#xD;
      which vascular pathology may contribute to LLD. If the study hypotheses are correct, this&#xD;
      crucial next step will support studies examining antidepressant properties of cardiovascular&#xD;
      drugs that may reverse vascular pathology and improve perfusion.&#xD;
&#xD;
      The investigators will pursue our initial goal by examining ASL predictors of nonremission to&#xD;
      a 12-week trial of sertraline. Forty LLD subjects will complete MRI, cognitive testing, and&#xD;
      hyperintensity assessment. ASL measured CBF will be obtained during a hypercapnia challenge&#xD;
      and at rest with room air. This will help determine if deficits in cerebrovascular reactivity&#xD;
      (CVR) and/or resting and on-demand CBF measures predict nonremission.&#xD;
&#xD;
      AIM: To test for differences in CVR and CBF in dorsal frontal cognitive control regions&#xD;
      between individuals who do and do not remit to a 12-week course of sertraline (defined as&#xD;
      MADRS ≤ 7).&#xD;
&#xD;
      Hypothesis 1: Compared with remitters, during a hypercapnia challenge nonremitters will&#xD;
      exhibit less CVR in the dlPFC and dAC.&#xD;
&#xD;
      Hypothesis 2: Compared with remitters, while breathing room air nonremitters will exhibit&#xD;
      lower resting CBF in the dorsal anterior cingulate (dAC) and dorsolateral prefrontal cortex&#xD;
      (dlPFC).&#xD;
&#xD;
      Exploratory Aim: To examine the relationship between ASL measures (CVR to hypercapnia and&#xD;
      resting CBF during normoxia) and performance in cognitive domains implicated in LLD treatment&#xD;
      outcomes. For this Aim, we will focus on functions involving the dlPFC and dAC, specifically&#xD;
      executive function and processing speed.&#xD;
&#xD;
      The study will enroll patients from clinical referrals and response to advertisements. In&#xD;
      these cases, potential participants will call our study contact number. Study staff will&#xD;
      describe the study to them, including a description of the study entry criteria. Those who&#xD;
      continue to be interested will then be scheduled for an evaluation. After scheduling, a study&#xD;
      physician will review their electronic medical record to assure that potential subjects meet&#xD;
      entry criteria.&#xD;
&#xD;
      Following policies of the Vanderbilt University Health System Institutional Review Board,&#xD;
      written informed consent will be obtained and documented by the study's Research Coordinator&#xD;
      before any study-related procedures are performed. The study coordinator will review study&#xD;
      procedures and the consent form with each potential participant. Each individual may take as&#xD;
      much time as they like to decide if they do or do not wish to participate. There is no&#xD;
      randomization. All participants receive open-label sertraline.&#xD;
&#xD;
      An initial evaluation will determine eligibility, depression severity, and evaluate medical&#xD;
      and psychiatric history. Participants will also complete a detailed battery assessing&#xD;
      cognitive function. During this time they will also complete the one-hour MRI session, which&#xD;
      includes measurement of cerebral perfusion and vascular reactivity.&#xD;
&#xD;
      They will then begin the 12-week trial of open-label sertraline, allowing titration up to the&#xD;
      maximum dose of 200mg daily. At the end of the study participants will be referred for&#xD;
      ongoing clinical treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of Depression</measure>
    <time_frame>Week 12</time_frame>
    <description>Montgomery-Asberg Depression Rating Scale (MADRS) is a measure of depression severity. This will be used to define remission as a score of 7 or less.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinician-rated Depression Severity</measure>
    <time_frame>Assessed every 2 weeks from baseline to week 12, change from baseline to week 12 is reported</time_frame>
    <description>Change in depression severity will be measured by the clinician-rated Montgomery Asberg Depression Rating Scale (MADRS), range of 0-60, with higher scores indicating more severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-rated Depression Severity</measure>
    <time_frame>Assessed every 2 weeks from baseline to week 12, change from baseline to week 12 is reported</time_frame>
    <description>Change in depression severity measured by the patient-rated Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16). The QIDS-SR16 is a self-report measure of depression severity with a range of 0-27, with higher scores indicative of more severe depression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50-200mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>50-200mg daily</description>
    <arm_group_label>Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 60 years or older.&#xD;
&#xD;
          2. Current diagnosis of major depressive disorder (DSM-IV-TR), single episode, recurrent&#xD;
             or chronic, without psychotic features, as detected by MINI and clinical exam.&#xD;
&#xD;
          3. Minimum MADRS score ≥ 15.&#xD;
&#xD;
          4. Mini-Mental State Exam ≥ 22.&#xD;
&#xD;
          5. Ability to read and write English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or past diagnoses of other Axis I psychiatric disorders, including panic&#xD;
             disorder and substance dependence.&#xD;
&#xD;
          2. Any use of illicit substances (such as marijuana or cocaine) or abuse of prescription&#xD;
             medications (such as benzodiazepines or opiates) within the last three months.&#xD;
&#xD;
          3. Presence of acute suicidality&#xD;
&#xD;
          4. Current or past psychosis&#xD;
&#xD;
          5. Known primary neurological disorder, including dementia, brain tumors, epilepsy,&#xD;
             Parkinson's disease, or demyelinating diseases&#xD;
&#xD;
          6. Chronic untreated medical disorders (including but not limited to hypertension,&#xD;
             hyperlipidemia, fibromyalgia, hypothyroidism, or any other disorder) where treatment&#xD;
             is warranted&#xD;
&#xD;
          7. Need for continuous oxygen use or any medical disorder where the hypercapnia challenge&#xD;
             would be contraindicated or put the subject at increased risk. This would include&#xD;
             active respiratory disease, chronic angina or other unstable cardiac conditions.&#xD;
&#xD;
          8. Any physical or intellectual disability affecting completion of assessments&#xD;
&#xD;
          9. MRI contraindications&#xD;
&#xD;
         10. Electroconvulsive therapy in last 6 months&#xD;
&#xD;
         11. Use of fluoxetine in the last 6 weeks. Occasional use of benzodiazepines or&#xD;
             non-benzodiazepine sedatives (such as zolpidem, eszopiclone, or zaleplon) during the&#xD;
             last month is allowable.&#xD;
&#xD;
         12. Known allergy or hypersensitivity to sertraline&#xD;
&#xD;
         13. A failed therapeutic trial of sertraline in the current depressive episode (defined as&#xD;
             at least 6 weeks of treatment at a daily dose of 100mg or higher)&#xD;
&#xD;
         14. Current or planned psychotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren D Taylor, MD, MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>July 1, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <results_first_submitted>May 16, 2017</results_first_submitted>
  <results_first_submitted_qc>June 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2017</results_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Warren Taylor</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Antidepressants</keyword>
  <keyword>Elderly</keyword>
  <keyword>Geriatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants taking ineffective antidepressant medications underwent a washout period. 10 recruited individuals were withdrawn after screening for a) concomitant medications (N=2), b) depression not severe (N=4), c) MRI contraindications (N=4)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sertraline</title>
          <description>50-200mg daily&#xD;
Sertraline: 50-200mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sertraline</title>
          <description>50-200mg daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.05" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale</title>
          <description>Depression rating scale, clinician rated, range 0-60, where higher scores indicate more severe depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.43" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quick Inventory of Depressive Symptoms</title>
          <description>Depression rating scale, self-report, Range 0-27, where higher scores indicate more severe depression</description>
          <population>Baseline data missing for 4 individuals (3 subject did not complete, 1 deviation where questionnaire was not provided to subject)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.94" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission of Depression</title>
        <description>Montgomery-Asberg Depression Rating Scale (MADRS) is a measure of depression severity. This will be used to define remission as a score of 7 or less.</description>
        <time_frame>Week 12</time_frame>
        <population>Individuals achieving remission of depression, defined as MADRS score of 7 or less.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>50-200mg daily&#xD;
Sertraline: 50-200mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Remission of Depression</title>
          <description>Montgomery-Asberg Depression Rating Scale (MADRS) is a measure of depression severity. This will be used to define remission as a score of 7 or less.</description>
          <population>Individuals achieving remission of depression, defined as MADRS score of 7 or less.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinician-rated Depression Severity</title>
        <description>Change in depression severity will be measured by the clinician-rated Montgomery Asberg Depression Rating Scale (MADRS), range of 0-60, with higher scores indicating more severe depression</description>
        <time_frame>Assessed every 2 weeks from baseline to week 12, change from baseline to week 12 is reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>50-200mg daily&#xD;
Sertraline: 50-200mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinician-rated Depression Severity</title>
          <description>Change in depression severity will be measured by the clinician-rated Montgomery Asberg Depression Rating Scale (MADRS), range of 0-60, with higher scores indicating more severe depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.14" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient-rated Depression Severity</title>
        <description>Change in depression severity measured by the patient-rated Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16). The QIDS-SR16 is a self-report measure of depression severity with a range of 0-27, with higher scores indicative of more severe depression.</description>
        <time_frame>Assessed every 2 weeks from baseline to week 12, change from baseline to week 12 is reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>50-200mg daily&#xD;
Sertraline: 50-200mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient-rated Depression Severity</title>
          <description>Change in depression severity measured by the patient-rated Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16). The QIDS-SR16 is a self-report measure of depression severity with a range of 0-27, with higher scores indicative of more severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Adverse events and serious adverse event definitions are concordant with clinicaltrials.gov definitions.&#xD;
Adverse events were assessed at every contact by asking individuals about any medical problems or potential side effects they were experiencing.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sertraline</title>
          <description>50-200mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry Eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include a small sample that reflects this is a pharmacoimaging study using MRI to examine imaging findings related to antidepressant treatment outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Warren D Taylor</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-936-3555</phone>
      <email>warren.d.taylor@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

